Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

COCP vs SRZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: COCP 2 – 3 SRZN (1 Tie) Matrix Metrics: COCP 2 – 5 SRZN

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). COCP carries a Unified Composite Score of 38.7/100 (SELL) at $1.01 (N/M Forward P/E, -3063.6% operating margin), whereas SRZN carries 33.2/100 (SELL) at $29.93 (N/M Forward P/E, -485.4% operating margin).

  • Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (38.7/100 SELL vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -3063.6% operating margin) and revenue trajectory (+408.6% vs. +26.9% YoY).
  • Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both COCP (38.7/100 SELL) and SRZN (33.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About COCP vs SRZN
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.01
+3.82% 1D
Market Cap $18.9M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 0.97β · 55% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.6 · SMA20: $1.00 · SMA50: $1.07
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.93
-7.38% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.28β · 66% Vol
Unified Composite Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.9% over 20 days), RSI 53
RSI-14: 53.1 · SMA20: $29.76 · SMA50: $26.28

6-Pillar Scorecard Institutional Category Breakdown (COCP 2 – 3 SRZN)

Columns: Metric · COCP · SRZN
1. Valuation Multiples COCP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 47.3x 48.3x
2. Growth & Scale SRZN
Revenue Growth (YoY) +26.9% +408.6%
Earnings Growth (YoY) +0.0% -37.0%
TTM Revenue (USD) $330,000 $11M
Market Cap $18.9M $602.5M
3. Profitability & Quality SRZN
Gross Margin N/A N/A
Operating Margin -3063.6% -485.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -311.7% -62.8%
4. Balance Sheet & Cash Flow COCP
Cash Generation (TTM) -$7.6M -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.3M Net Cash $95M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 72.0% (5th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: COCP (2) vs SRZN (5)
Institutional Metric COCP SRZN Criterion Row Edge
Market Capitalization
Scale
$18.9M $602.5M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+26.9% +408.6% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-3063.6% -485.4% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-311.7% -62.8% Higher ROE SRZN
52-Week Range Position
Momentum
20% ($1–$2) 69% ($12–$38) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
0.97β · 55% Vol 1.28β · 66% Vol Lower Realized Risk COCP
Unified Institutional Score
Composite Signal
38.7 / 100 (SELL) 33.2 / 100 (SELL) Higher Composite COCP
Trailing 12M Revenue (USD)
Operating Scale
$330,000 $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 47.3x EV/Rev N/M PEG · 48.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$7.6M ($3.3M Net Cash) -$31M ($95M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +18.34 pp
COCP: +7.23% · SRZN: +25.57%
3M Horizon SRZN +36.03 pp
COCP: -11.35% · SRZN: +24.68%
6M Horizon SRZN +28.81 pp
COCP: -11.74% · SRZN: +17.07%
1Y Horizon SRZN +132.08 pp
COCP: -1.46% · SRZN: +130.62%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period COCP Revenue SRZN Revenue COCP Op. Margin SRZN Op. Margin Margin Leader
FY2011 $10M N/A -30.6% N/A COCP
FY2019 $10M N/A -737.4% N/A COCP
FY2020 $0M N/A -476.0% N/A COCP
FY2022 N/A $10M N/A -354.7% SRZN
FY2024 N/A $10M N/A -239.7% SRZN
FY2025 N/A $0M N/A -1210.6% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
38d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $18.9M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ COCP vs SRZN Key Questions & Quantitative Answers

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). COCP carries a Unified Composite Score of 38.7/100 (SELL) at $1.01 (N/M Forward P/E, -3063.6% operating margin), whereas SRZN carries 33.2/100 (SELL) at $29.93 (N/M Forward P/E, -485.4% operating margin). Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (38.7/100 SELL vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -3063.6% operating margin) and revenue trajectory (+408.6% vs. +26.9% YoY). Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both COCP (38.7/100 SELL) and SRZN (33.2/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SRZN leads the Growth & Scale pillar: COCP posts +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 6-period historical trajectory (FY2011 to FY2025), COCP cumulative revenue shifted +0.0% while SRZN shifted +0.0%. In operating R&D and SG&A reinvestment, COCP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.

COCP screens cheaper on headline valuation multiples. COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 47.3x EV/Revenue (unreported FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against COCP (-311.7% ROE) versus SRZN (-62.8% ROE) capital efficiency.

In options market volatility and institutional positioning, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.97β · 55% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.28β · 66% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.